What do systematic reviews say?

Chlorhexidine mouthrinse (any concentration; 0.05% to 0.2%) used in conjunction with mechanical oral hygiene procedures vs Placebo/control mouthrinse, or no mouthrinse (mechanical oral hygiene alone); controls pooled (protocol's separate comparisons versus mechanical oral hygiene alone and versus placebo/control merged)

Chlorhexidine mouthrinse (any concentration; 0.05% to 0.2%) used in… led to lower gingival bleeding (various bleeding indices) compared with placebo/control mouthrinse, or no mouthrinse (mechanical oral…; GRADE not reported.

• Chlorhexidine mouthrinse as an adjunctive treatment for gingival health 2017 · Cochrane All outcomes

  4 to 6 weeks
  SMD -0.56 [-0.79, -0.33]
  8 studies · 649 participants
  GRADE not reported
• Chlorhexidine mouthrinse as an adjunctive treatment for gingival health 2017 · Cochrane All outcomes

  6 months
  SMD -0.72 [-1.02, -0.42]
  8 studies · 1132 participants
  GRADE not reported

Chlorhexidine mouthrinse (any concentration; 0.05% to 0.2%) used in conjunction with mechanical oral hygiene procedures vs Placebo/control mouthrinse, or no mouthrinse (mechanical oral hygiene alone); controls pooled (protocol's separate comparisons versus mechanical oral hygiene alone and versus placebo/control merged)

Chlorhexidine mouthrinse (any concentration; 0.05% to 0.2%) used in… leads to lower dental plaque (various plaque indices) compared with placebo/control mouthrinse, or no mouthrinse (mechanical oral… (high certainty).

• Chlorhexidine mouthrinse as an adjunctive treatment for gingival health 2017 · Cochrane All outcomes

  6 months
  SMD -1.43 [-1.76, -1.10]
  11 studies · 2075 participants
  High
• Chlorhexidine mouthrinse as an adjunctive treatment for gingival health 2017 · Cochrane All outcomes

  4 to 6 weeks
  SMD -1.45 [-1.90, -1.00]
  12 studies · 950 participants
  High

Chlorhexidine mouthrinse (any concentration; 0.05% to 0.2%) used in conjunction with mechanical oral hygiene procedures vs Placebo/control mouthrinse, or no mouthrinse (mechanical oral hygiene alone); controls pooled (protocol's separate comparisons versus mechanical oral hygiene alone and versus placebo/control merged)

• Chlorhexidine mouthrinse as an adjunctive treatment for gingival health 2017 · Cochrane All outcomes
  SoF narrative row (Other adverse effects): 22 trials reported at least 1 adverse effect apart from extrinsic tooth staining and calculus formation in the chlorhexidine rinse arms. The adverse effects most commonly…
  22 studies
  GRADE not reported

Chlorhexidine mouthrinse (any concentration; 0.05% to 0.2%) used in conjunction with mechanical oral hygiene procedures vs Placebo/control mouthrinse, or no mouthrinse (mechanical oral hygiene alone); controls pooled (protocol's separate comparisons versus mechanical oral hygiene alone and versus placebo/control merged)

Chlorhexidine mouthrinse (any concentration; 0.05% to 0.2%) used in… led to higher extrinsic tooth staining (various staining indices) compared with placebo/control mouthrinse, or no mouthrinse (mechanical oral…; GRADE not reported.

• Chlorhexidine mouthrinse as an adjunctive treatment for gingival health 2017 · Cochrane All outcomes

  6 months
  SMD 1.54 [1.22, 1.86]
  4 studies · 323 participants
  GRADE not reported
• Chlorhexidine mouthrinse as an adjunctive treatment for gingival health 2017 · Cochrane All outcomes

  4 to 6 weeks
  SMD 1.07 [0.80, 1.34]
  8 studies · 415 participants
  Moderate

Corticosteroids vs placebo

Corticosteroids may leads to higher clinical improvement (dichotomous) compared with placebo (low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 1.74 [1.08, 2.8]
  6 studies · 583 participants
  Low

Corticosteroids vs placebo

Corticosteroids probably leads to higher histological improvement (dichotomous) compared with placebo (moderate certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 4.58 [1.66, 12.62]
  3 studies · 280 participants
  Moderate

Leukotriene receptor antagonist vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Leukotriene receptor antagonist vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Leukotriene receptor antagonist vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Leukotriene receptor antagonist vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Leukotriene receptor antagonist vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Leukotriene receptor antagonist vs placebo

It is very uncertain whether leukotriene receptor antagonist changes withdrawals due to adverse events at 26 weeks compared with placebo (very low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 2.1 [0.21, 21.39]
  1 study · 41 participants
  Very low

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

It is very uncertain whether mepolizumab 10 mg/kg changes histological improvement at 12 weeks (dichotomous) compared with mepolizumab 0.55 mg/kg (very low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 1.19 [0.37, 3.77]
  1 study · 39 participants
  Very low

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Corticosteroids vs placebo

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 269 participants
  Moderate

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

It is very uncertain whether mepolizumab 10 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 0.55 mg/kg (very low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 0.63 [0.12, 3.38]
  1 study · 39 participants
  Very low